Cargando…

DPP-4 Inhibitor in Type 2 Diabetes Mellitus Patient with Non-Alcoholic Fatty Liver Disease: Achieving Two Goals at Once?

Detalles Bibliográficos
Autor principal:	Bae, Ji Cheol
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Endocrine Society 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9816515/ https://www.ncbi.nlm.nih.gov/pubmed/36604957 http://dx.doi.org/10.3803/EnM.2022.605

Ejemplares similares

DPP-4 Inhibitors Improve Liver Dysfunction in Type 2 Diabetes Mellitus
por: Kanazawa, Ippei, et al.
Publicado: (2014)

The efficacy and safety of once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus: A systemic review and meta-analysis
por: Wang, Xianying, et al.
Publicado: (2018)

A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus
por: Gantz, Ira, et al.
Publicado: (2017)

Efficacy and Patient Satisfaction of Dipeptidyl Peptidase-4 Inhibitor After Switching From Once-Daily DPP-4 Inhibitor to Once-Weekly Regimen
por: Suzuki, Katsunori, et al.
Publicado: (2018)

Achieving the Millennium Development Goals in Bangladesh
por: Sack, David A.
Publicado: (2008)

Step-by-Step to Achieve our Goals
por: Braile, Domingo M.
Publicado: (2016)

Achieving the goals of the ISSCR standards initiative
por: Pera, Martin F.
Publicado: (2023)

Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once?
por: Tacelli, Matteo, et al.
Publicado: (2018)

Randomized clinical trial comparing the efficacy and safety of treatment with the once‐weekly dipeptidyl peptidase‐4 (DPP‐4) inhibitor omarigliptin or the once‐daily DPP‐4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy
por: Goldenberg, Ronald, et al.
Publicado: (2017)

The role of health in achieving the sustainable development goals
por: Acharya, Shambhu, et al.
Publicado: (2018)

Association of metabolic dysfunction-associated fatty liver disease, type 2 diabetes mellitus, and metabolic goal achievement with risk of chronic kidney disease
por: Su, Weitao, et al.
Publicado: (2022)

Associations of lipid parameters with non-alcoholic fatty liver disease in type 2 diabetic patients according to obesity status and metabolic goal achievement
por: Zhu, Zengzhe, et al.
Publicado: (2022)

Elevated hepatic DPP4 activity promotes insulin resistance and non-alcoholic fatty liver disease
por: Baumeier, Christian, et al.
Publicado: (2017)

The effect of moderate alcohol consumption on nonalcoholic fatty liver disease
por: Park, Ji-Won, et al.
Publicado: (2023)

First anniversary of Molecular Cancer: achievements and future goals
por: Deora, Arun B, et al.
Publicado: (2003)

How to achieve nutrition goals by actual nutrition guidelines
por: Stoppe, Christian, et al.
Publicado: (2019)

DPP-4 inhibitors and severe course of illness in patients with COVID-19
por: Bouhanick, Béatrice, et al.
Publicado: (2021)

Managing non‐alcoholic fatty liver disease in diabetes: Challenges and opportunities
por: Lee, Chi‐Ho, et al.
Publicado: (2016)

Bringing population mobility into focus to achieve HIV prevention goals
por: Camlin, Carol S, et al.
Publicado: (2018)

Strategies for editors to contribute for the achievement of the Sustainable Development Goals by 2030
por: Nassi-Calò, Lilian
Publicado: (2023)

Saxagliptin: A Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
por: Shubrook, Jay, et al.
Publicado: (2011)

The Relationship between Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease Measured by Controlled Attenuation Parameter
por: Chon, Young Eun, et al.
Publicado: (2016)

Reducing the Delay Between Stroke Onset and Hospital Arrival: Is It an Achievable Goal?
por: Reeves, Mathew J.
Publicado: (2012)

Transforming the Agri-food Sector in India for Achieving the Sustainable Development Goals
por: Pathak, Himanshu
Publicado: (2023)

Contribution of Enzyme Catalysis to the Achievement of the United Nations’ Sustainable Development Goals
por: Holtmann, Dirk, et al.
Publicado: (2023)

Non-Alcoholic Fatty Liver Disease and Its Association With Diabetes Mellitus
por: Padda, Jaskamal, et al.
Publicado: (2021)

Potential repurposing of DPP4 inhibitors for target therapy resistance in renal cell carcinoma
por: Horie, Kuniko, et al.
Publicado: (2023)

A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin
por: Lee, Seung-Hwan, et al.
Publicado: (2017)

Nonalcoholic Fatty Liver Disease Is a Stepping Stone in the Path toward Diabetes Mellitus
por: Heo, Nae-Yun
Publicado: (2019)

Non-invasive biomarkers of liver fibrosis in non-alcoholic fatty liver disease
por: Basheer, Maamon, et al.
Publicado: (2023)

How to optimize the outcome of liver transplantation for non-alcoholic fatty liver disease
por: Song, Byeong Geun, et al.
Publicado: (2023)

Relationship between the dynamics of non-alcoholic fatty liver disease and incident diabetes mellitus
por: Han, Ji Eun, et al.
Publicado: (2022)

The growing burden of non-alcoholic fatty liver disease on mortality
por: Cho, Ju-Yeon, et al.
Publicado: (2023)

Optimal diagnosis and management of non-alcoholic fatty liver disease
Publicado: (2022)

Type 2 diabetes mellitus prevention strategy: Target and goal in Japanese men
por: Iwahashi, Hiromi, et al.
Publicado: (2016)

DPP4 inhibition prevents AKI
por: Reichetzeder, Christoph, et al.
Publicado: (2017)

Research on community-based health workers is needed to achieve the sustainable development goals
por: Maher, Dermot, et al.
Publicado: (2016)

What is a good medical journal? Has KJT succeeded in achieving this goal?
por: Yun, Ik Jin
Publicado: (2022)

Medicinal Chemistry and Applications of Incretins and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus
por: Lotfy, Mohamed, et al.
Publicado: (2011)

The Dipeptidyl Peptidase (DPP)-4 Inhibitors for Type 2 Diabetes Mellitus in Challenging Patient Groups
por: Kountz, David
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_mn6mb7c8il5ul8rn8dvobi4o9a